Home › Targets › PDE4D
Radioligand therapy target profile

PDE4D: IHC Expression in Cancer and Radioligand Target Profile

phosphodiesterase 4D · Ensembl ENSG00000113448 · Data updated 2026-11-01

PDE4D, phosphodiesterase 4D, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, PDE4D staining is highest in colorectal cancer (100% of samples positive), melanoma (100% of samples positive) and prostate cancer (100% of samples positive). Clinical status: FDA-approved drug (any modality).

Is PDE4D the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze PDE4D free
LocalizationCell-Surface
Top cancer (IHC)Colorectal Cancer
InternalizationNot assessed
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.48

Is PDE4D a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

PDE4D IHC staining by cancer type

Protein expression of PDE4D across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Colorectal Cancer0.94High100%
Melanoma0.93High100%
Prostate Cancer0.89High100%
Endometrial Cancer0.88High100%
Lung Cancer0.81High100%
Neuroendocrine Tumors0.75High100%
Breast Cancer0.74High100%
Bladder Cancer0.70High100%
Ovarian Cancer0.69High100%
Cervical Cancer0.69High100%
Gastric Cancer0.69High100%
Liver Cancer0.69High100%
Head and Neck Cancer0.67High100%
Kidney Cancer0.67High100%
Thyroid Cancer0.67High100%
Pancreatic Cancer0.64High92%
Lymphoma0.58High100%
Glioma0.57High100%
Skin Cancer0.52High91%
Testicular Cancer0.46Medium100%

Is PDE4D internalized?

Nuclens has not yet extracted internalization evidence for PDE4D. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.

PDE4D clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for PDE4D yet. Search ClinicalTrials.gov for PDE4D trials.

PDE4D normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See PDE4D in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

PDE4D gene essentiality (DepMap)

CRISPR knockout effect across 1258 cancer cell lines: 0.02 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related colorectal cancer radioligand targets

c-MET (MET) · HER3 (ERBB3) · EGFR · FAP · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2

See all radioligand therapy targets in colorectal cancer.

See how PDE4D ranks against 15,000 targets for your indication.

Analyze PDE4D free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is PDE4D the right target for your program? · 5 free analyses, no card Analyze PDE4D free